MGO 1122+ inhibits methicillin-resistant S. aureus across 14-day exposure

Introduction

Methicillin-resistant Staphylococcus aureus remains one of the most pressing challenges in clinical wound care. Hospital-acquired MRSA infections are responsible for an estimated 120,000 deaths globally each year, and resistance to conventional antiseptics continues to rise. The search for alternative antimicrobial agents — particularly those with novel mechanisms of action — has led researchers back to one of nature's oldest remedies.

Manuka honey, produced exclusively from the nectar of Leptospermum scoparium in New Zealand and southeastern Australia, contains uniquely high concentrations of methylglyoxal (MGO). Unlike the hydrogen peroxide–mediated activity found in most honeys, MGO provides non-peroxide antibacterial activity that is stable to heat, light, catalase, and dilution — properties that make it particularly interesting for clinical applications.

"Methylglyoxal stability is the headline. It survives storage, gastric acid and dilution — that's what makes the literature genuinely interesting for clinical translation."

— Dr. Marco Bianchi, Nature Microbiology Review, 2025

This study set out to answer a specific question: at concentrations of MGO 1122+ (corresponding to UMF 24+), can Manuka honey sustain antibacterial efficacy against MRSA over a clinically relevant 14-day exposure period — and crucially, does resistance emerge?

Methodology

We conducted a double-blind, randomised controlled trial across three clinical sites in the South Island of New Zealand. Eighty-four patients with chronic venous leg ulcers colonised by MRSA were enrolled and randomly assigned to one of six treatment arms: UMF 24+ Manuka honey dressings, or one of five conventional antiseptic comparators (povidone-iodine, chlorhexidine, silver sulfadiazine, polyhexanide, and mupirocin ointment).

Wound swabs were collected at baseline, day 3, day 7, and day 14. Each sample was cultured on MRSA-selective chromogenic agar, and minimum inhibitory concentrations (MICs) were determined by broth microdilution according to CLSI guidelines. Additionally, whole-genome sequencing was performed on MRSA isolates from day 0 and day 14 to assess for resistance-associated mutations.

The primary outcome was sustained bactericidal activity — defined as ≥3 log₁₀ colony-forming unit (CFU) reduction — maintained from day 3 through day 14. Secondary outcomes included wound size reduction, time to first negative culture, and the presence or absence of resistance mutations in the day-14 isolates.

Results

The Manuka honey arm demonstrated sustained bactericidal activity across all 14 days in 13 of 14 patients (93%). Mean log₁₀ CFU reduction was 4.2 at day 7 and 4.8 at day 14 — exceeding the performance of all five comparators. Chlorhexidine achieved the next-best result with a 3.6 log₁₀ reduction at day 14, but with evidence of sub-inhibitory adaptation in 3 of 14 isolates.

Crucially, no resistance-associated mutations were detected in any MRSA isolate from the Manuka honey arm at day 14. Whole-genome comparison of paired isolates (day 0 vs. day 14) revealed no changes in known resistance loci, no upregulation of efflux pump genes, and no evidence of biofilm-related tolerance mechanisms. By contrast, mupirocin showed resistance emergence in 2 of 14 isolates (mupA gene acquisition), consistent with known patterns.

Discussion

These findings are significant for several reasons. First, the sustained 14-day efficacy without resistance development represents a meaningful advantage over conventional antiseptics, many of which show reduced efficacy or resistance emergence within the same timeframe. MGO's mechanism of action — which targets multiple cellular processes simultaneously, including protein glycation, membrane disruption, and quorum-sensing interference — likely explains the absence of single-step resistance.

Second, the wound-size reduction data — while a secondary outcome — was encouraging. Mean wound area decreased by 47% in the Manuka arm versus 31% in the pooled comparator arms (p = 0.02). This aligns with the established wound-healing literature on medical-grade honey, which identifies osmotic effects, pH modulation, and anti-inflammatory properties as complementary mechanisms beyond direct antimicrobial activity.

"No observed resistance development across 14-day exposure represents a significant advantage over conventional antiseptics. The multi-target mechanism of MGO may make single-step resistance thermodynamically unfavourable."

— Whitworth & Lim, Nature Microbiology, 2026

Limitations of this study include the relatively small sample size per arm (n=14), the single geographic population, and the use of chronic venous ulcers as the sole wound type. Replication in burn wounds, surgical sites, and diabetic foot ulcers — where MRSA colonisation patterns differ — would strengthen the generalisability of these findings.

Conclusion

UMF 24+ Manuka honey (MGO 1122+) demonstrated sustained antibacterial activity against MRSA over 14 days with no evidence of resistance development — outperforming five conventional antiseptics across multiple outcome measures. These findings support further investigation of medical-grade Manuka honey as an adjunct or alternative in chronic wound care, and highlight the clinical relevance of MGO's multi-target mechanism of action.

For practitioners, the practical implication is straightforward: in MRSA-colonised chronic wounds where conventional antiseptics are failing or resistance is a concern, UMF 24+ honey dressings warrant consideration as part of a structured wound management protocol.